Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer

Article Properties
Cite
Palácová, Markéta. “Sacituzumab Govitecan in the Treatment of Metastatic Triple Negative Breast Cancer”. Onkologie, vol. 17, no. 3, 2023, pp. 160-3, https://doi.org/10.36290/xon.2023.032.
Palácová, M. (2023). Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer. Onkologie, 17(3), 160-163. https://doi.org/10.36290/xon.2023.032
Palácová, Markéta. “Sacituzumab Govitecan in the Treatment of Metastatic Triple Negative Breast Cancer”. Onkologie 17, no. 3 (2023): 160-63. https://doi.org/10.36290/xon.2023.032.
Palácová M. Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer. Onkologie. 2023;17(3):160-3.
Refrences
Title Journal Journal Categories Citations Publication Date
Cancer statistic review. 1975 2016
10.1056/NEJMoa2028485
10.1200/JCO.2020.38.15_suppl.1000
10.1016/S1470-2045(19)30689-8
10.1158/1078-0432.CCR-14-0432